Compositions and formulations for treatment of malignancies
AssigneeNeugate Pharma, LLC aka Neugate Theranostics
InventorYvonne Kew
Life of this patent
Estimating the term…
Abstract
The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.
Claims15
A composition for potentiating chemotherapy and/or radiation therapy in a subject with a malignancy, comprising a pharmaceutically acceptable dosage of a composition that activates the subject's immune system, wherein the composition activates an increase in the ratio of IL-15/IL-6 expression and/or activity in a sample from the subject, and wherein the administration of the composition results in an improved clinical outcome in the subject.
A method of assessing a patient for likelihood of responding to a therapeutic intervention for a malignancy, comprising:
- requesting a test to determine the ratio of IL-15/IL-6 expression and/or activity in a sample from the subject;
- and
- administering therapeutic intervention to the subject if the ratio of IL-15/IL-6 expression and/or activity is one or greater.
A method of treating a malignancy, the method comprising:
- administering to a subject a composition that increases the IL-15 expression levels in a sample from the subject, wherein the increase in IL-15 is associated with an increase in the antibody-dependent cellular cytotoxicity (ADCC) of natural killer (NK cells), such that the increase in ADCC of the NK cells results in an improved response to one or more therapeutic interventions for the malignancy.
Dependencies are inferred from the claim text.